{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:58:30Z","timestamp":1791655110958,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"am","delay-in-days":453,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.euf.2021.06.007","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T13:47:11Z","timestamp":1624456031000},"page":"1226-1237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Prognostic Implications of Treatment Delays for Patients with Non\u2013muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7947-0395","authenticated-orcid":false,"given":"Said","family":"Ourfali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Matillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakim","family":"Fassi-Fehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Benoit-Janin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Badet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2021.06.007_bib0005","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euf.2021.06.007_bib0010","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u20142019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2021.06.007_bib0015","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2021.06.007_bib0020","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2010.04.019","article-title":"Second resection for non-muscle-invasive bladder carcinoma: current role and future perspectives","volume":"58","author":"Babjuk","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2021.06.007_bib0025","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000491642","article-title":"The optimal timing of restaging resection before introduction of bacillus Calmette-Guerin immunotherapy in patients with high-risk non-muscle-invasive bladder cancer","volume":"102","author":"Krajewski","year":"2019","journal-title":"Urol Int"},{"key":"10.1016\/j.euf.2021.06.007_bib0030","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0022-5347(05)01002-5","article-title":"The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial","volume":"175","author":"Divrik","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2021.06.007_bib0035","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/bju.13354","article-title":"The impact of re-TUR on clinical outcomes in a large multi-centre cohort of T1-HG\/G3 patients treated with BCG","volume":"118","author":"Gontero","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2021.06.007_bib0040","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(99)06093-6","article-title":"Early Lung Cancer Action Project: overall design and findings from baseline screening","volume":"354","author":"Henschke","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2021.06.007_bib0045","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1097\/01.ju.0000086828.26001.ca","article-title":"Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage","volume":"170","author":"Chang","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2021.06.007_bib0050","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0022-5347(05)64047-5","article-title":"An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma","volume":"169","author":"S\u00e1nchez-Ortiz","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2021.06.007_bib0055","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.eururo.2006.05.046","article-title":"Delay in the surgical treatment of bladder cancer and survival: systematic review of the literature","volume":"50","author":"Fahmy","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2021.06.007_bib0060","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.eururo.2007.06.030","article-title":"Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?","volume":"53","author":"Denzinger","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2021.06.007_bib0065","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00345-009-0402-4","article-title":"Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3)","volume":"27","author":"Hautmann","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2021.06.007_bib0070","doi-asserted-by":"crossref","first-page":"E284","DOI":"10.1111\/j.1464-410X.2010.09980.x","article-title":"Early vs delayed radical cystectomy for \u201chigh-risk\u201d carcinoma not invading bladder muscle: delay of cystectomy reduces cancer-specific survival","volume":"108","author":"J\u00e4ger","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2021.06.007_bib0075","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1002\/cncr.25310","article-title":"Delays in diagnosis and bladder cancer mortality","volume":"116","author":"Hollenbeck","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2021.06.007_bib0080","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1046\/j.1464-410X.2002.02776.x","article-title":"Delay and survival in bladder cancer","volume":"89","author":"Wallace","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2021.06.007_bib0085","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.euf.2015.01.001","article-title":"A comparative analysis of the influence of gender, pathway delays, and risk factor exposures on the long-term outcomes of bladder cancer","volume":"1","author":"Bryan","year":"2015","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2021.06.007_bib0090","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2021.06.007_bib0095","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2021.06.007_bib0100","doi-asserted-by":"crossref","first-page":"874","DOI":"10.2307\/2532989","article-title":"Hazard function estimation using B-splines","volume":"51","author":"Rosenberg","year":"1995","journal-title":"Biometrics"},{"key":"10.1016\/j.euf.2021.06.007_bib0105","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non\u2013muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2021.06.007_bib0110","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2009.04.009","volume":"56","author":"J\u00e4rvinen","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2021.06.007_bib0115","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/bju.13102","article-title":"Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical bacillus Calmette-Gu\u00e9rin","volume":"116","author":"Baltac\u0131","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2021.06.007_bib0120","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.lungcan.2017.08.011","article-title":"Timeliness of access to lung cancer diagnosis and treatment: a scoping literature review","volume":"112","author":"Jacobsen","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.euf.2021.06.007_bib0125","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1002\/cncr.32048","article-title":"Delays in radical cystectomy for muscle-invasive bladder cancer","volume":"125","author":"Chu","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2021.06.007_bib0130","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1245\/s10434-018-6615-2","article-title":"Timing and delays in breast cancer evaluation and treatment","volume":"25","author":"Bleicher","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.euf.2021.06.007_bib0135","doi-asserted-by":"crossref","first-page":"237.e9","DOI":"10.1016\/j.urolonc.2017.12.015","article-title":"Discrepancies in staging, treatment, and delays to treatment may explain disparities in bladder cancer outcomes: an update from the National Cancer Data Base (2004\u20132013)","volume":"36","author":"Weiner","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2021.06.007_bib0140","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S1470-2045(08)70032-9","article-title":"Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis","volume":"9","author":"Halpern","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2021.06.007_bib0145","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.juro.2010.12.049","article-title":"Transitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007)","volume":"185","author":"Mallin","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2021.06.007_bib0150","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.euf.2020.05.020","article-title":"A systematic review on guidelines and recommendations for urology standard of care during the COVID-19 pandemic","volume":"6","author":"Heldwein","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2021.06.007_bib0155","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00345-019-02628-7","article-title":"Meta-analysis of efficacy and safety of continuous saline bladder irrigation compared with intravesical chemotherapy after transurethral resection of bladder tumors","volume":"37","author":"Zhou","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2021.06.007_bib0160","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.euf.2019.04.002","article-title":"Recurrence rate and cost consequence of the shortage of bacillus Calmette-Gu\u00e9rin Connaught strain for bladder cancer patients","volume":"7","author":"Ourfali","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2021.06.007_bib0165","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2021.06.007_bib0170","article-title":"Assessing the Impact of the Absence of Detrusor Muscle in Ta Low-grade Urothelial Carcinoma of the Bladder on Recurrence-free Survival","author":"Mastroianni","year":"2020","journal-title":"Eur Urol Focus"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456921001693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456921001693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:55:27Z","timestamp":1762498527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456921001693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2405456921001693"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2021.06.007","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Implications of Treatment Delays for Patients with Non\u2013muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2021.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}